{
    "organizations": [],
    "uuid": "2902b1b8fe2d24a09adee7b603507513b60d68dc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aptose-reports-qtrly-loss-of-012-p/brief-aptose-reports-qtrly-loss-of-0-12-per-share-idUSASC09TV4",
    "ord_in_thread": 0,
    "title": "BRIEF-Aptose Reports Qtrly Loss Of $0.12‍​ Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Aptose Biosciences Inc:\n* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017\n* APTOSE BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.12‍​\n* APTOSE BIOSCIENCES - ‍TOTAL CASH AND CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017 WERE $11.4 MILLION​\n* APTOSE BIOSCIENCES - ‍BASED ON CURRENT ESTIMATIONS, CO HAS SUFFICIENT RESOURCES TO FUND RESEARCH, DEVELOPMENT AND OPERATIONS INTO Q1 2019​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ",
    "published": "2018-03-28T04:23:00.000+03:00",
    "crawled": "2018-03-28T18:48:39.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "aptose",
        "bioscience",
        "inc",
        "aptose",
        "report",
        "result",
        "fourth",
        "quarter",
        "year",
        "ended",
        "december",
        "aptose",
        "bioscience",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "aptose",
        "bioscience",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "dec",
        "aptose",
        "bioscience",
        "current",
        "estimation",
        "co",
        "sufficient",
        "resource",
        "fund",
        "research",
        "development",
        "operation",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}